-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $60

Benzinga·11/10/2026 12:13:35
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $65 to $60.